Unveiling neuroplastic mechanisms in a periphery-to- brain crosstalk in an experimental model of anorexia nervosa

Unveiling beneficial effects of a peanut butter meal on postprandial neutrophils activation and endothelial dysfunction in pre-clinical cardiovascular disease

Cognitive control of food reward: role of glutamate in an experimental model of anorexia nervosa - 2° anno

Understanding allergen potency: role of protein kinase C activation in the vigor of dendritic cell

Development of a mechanistic-based in vitro method to estimate the sensitization induction level for contact allergens

HDL quality vs quantity in coronary artery disease (HDL)

Time dependent Structural and Functional Changes Induced by Ketamine in the Glutamate System in Rat Model of depression

Validating ADAM10 as therapeutic target for dementia

Cotratto di collaborazione per la realizzazione dell'attività di ricerca avente per oggetto: Psychopharmacology and molecular psychiatry in order to carry out, among other activities, microarray analyses on human RNA samples from depressed patients and cellular neurones

Interplay between Androgenic/Anabolic Steroid and IGF-1 Signaling in Amyotrophic Lateral Sclerosis

Unrevealing mechanisms of gabaergic control of neuro-schwann cell interaction in peripheral neuropathies

Development of innovative tools for Alzheimer Disease therapy

The role of lipid synthesis in neuroprotection from diabetic neuropathy

Gametocyte Assay for MAlaria (GAM) for Novel Anti-Transmission Drugs

Validation of a human T cell activation assay to identify immunosuppressive compounds

Selective autophagic response to proteotoxicity in motorneurons and muscle of motor neuron diseases

Innate Immune Activation in Malaria

Unveiling the impact of ASGR1 deficiency on the immunoinflammatory signature during atherogenesis (ASGR1 )

Bioinformatics and cell reprogramming to develop an in vitro platform to discover new drugs for progressive multiple sclerosis (BRAVEinMS)

Bioinformatics and cell reprogramming to develop an in vitro platform to discover new drugs for progressive multiple sclerosis (BRAVEinMS)